GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » Gross Profit

Ikena Oncology (Ikena Oncology) Gross Profit : $3.85 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ikena Oncology Gross Profit?

Ikena Oncology's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Ikena Oncology's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $3.85 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Ikena Oncology's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Ikena Oncology's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Ikena Oncology's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Ikena Oncology had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Ikena Oncology Gross Profit Historical Data

The historical data trend for Ikena Oncology's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ikena Oncology Gross Profit Chart

Ikena Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
13.75 9.19 30.99 15.62 9.16

Ikena Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 2.00 1.19 0.66 -

Competitive Comparison of Ikena Oncology's Gross Profit

For the Biotechnology subindustry, Ikena Oncology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ikena Oncology's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ikena Oncology's Gross Profit distribution charts can be found below:

* The bar in red indicates where Ikena Oncology's Gross Profit falls into.



Ikena Oncology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Ikena Oncology's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=9.16 - 0
=9.16

Ikena Oncology's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.85 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Ikena Oncology's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Ikena Oncology  (NAS:IKNA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Ikena Oncology had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Ikena Oncology Gross Profit Related Terms

Thank you for viewing the detailed overview of Ikena Oncology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Ikena Oncology (Ikena Oncology) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 101, Boston, MA, USA, 02210
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Executives
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Jotin Marango officer: CFO & Head of Corp. Dev. C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Francisco Oliveira officer: Principal Accounting Officer IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210
Richard Wooster director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Xiaoyan Michelle Zhang officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Maria Koehler director C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mark Manfredi director, officer: President & CEO C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Maude Tessier officer: Chief Business Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey Ecsedy officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139